OCS · Oculis Holding AG
United States · RS rating 11 · As of 2026-11-03
| Price | 7.63 USD |
|---|---|
| 1-day change | -1.0% |
| RS rating (overall / 1M / 3M / 12M) | 11 / 34 / 15 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 4 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -31.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +76.6% |
| Market cap (USD) | $1.6B |